Dry Powder Inhalers (DPI)

Soluplus is a polymer that has been explored to prepare nanocomposites for pulmonary drug delivery and is non-toxic. However, its aerosolization attributes when spray-dried have not been investigated. Hence, this work aimed to investigate the aerosol performance of soluplus-based spray-dried…
Read More...

Judgment of the General Court in Joined Cases T-279/20, T-288/20 and T-283/20 | CWS Powder Coatings and Others v Commission First, the Commission made a manifest error in its assessment of the reliability and acceptability of the study on which the classification was based and, second, it…
Read More...

Dry powder inhalers (DPIs) are regularly used to treat respiratory diseases. Adding extrinsic fine excipient particles to the blend of active pharmaceutical ingredient (API) and carrier is an established strategy to improve aerosolization efficiency during pulmonary drug delivery. Different amounts…
Read More...

MEGGLE is a pioneer in co-processing technologies that allow simple, robust formulation development and manufacture. Through co-processing, MEGGLE developed highly functional excipients possessing unique qualities for directly compressible immediate and sustained release pharmaceutical solid dosage…
Read More...

MEGGLE is a pioneer in co-processing technologies that allow simple, robust formulation development and manufacture. Through co-processing, MEGGLE developed highly functional excipients possessing unique qualities for directly compressible immediate and sustained release pharmaceutical solid dosage…
Read More...

Purpose The objective of this study was to incorporate a passive cyclic loading strategy into the infant air-jet dry powder inhaler (DPI) in a manner that provides high efficiency aerosol lung delivery and is insensitive to powder mass loadings and the presence of downstream pulmonary mechanics.…
Read More...

Dry powder inhalers (DPIs) can be used with a wide range of drugs such as small molecules and biologics and offer several advantages for inhaled therapy. Early DPI products were intended to treat asthma and lung chronic inflammatory disease by administering low-dose, high-potency drugs blended with…
Read More...

While all the siRNA drugs on the market target the liver, the lungs offer a variety of currently undruggable targets which could potentially be treated with RNA therapeutics. Hence, local, pulmonary delivery of RNA nanoparticles could finally enable delivery beyond the liver. The administration of…
Read More...

FlowLac by MEGGLE is directly compressible lactose having a spherical agglomerate shape, consisting of small alpha-lactose monohydrate crystals bound by amorphous lactose. It  is produced by spray-drying a suspension of fine milled alpha-lactose monohydrate crystals in a solution of lactose. When…
Read More...

RetaLac® by MEGGLE is a co-processed excipient comprising of equal parts of milled alpha-lactose monohydrate and hypromellose (USP substitution type 2208) with a nominal viscosity of 4000 cps. A specialized spray-agglomeration process generates textured, highly structured particles with d50 in…
Read More...